Insulin aspart (Fiasp) vs insulin glulisine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline
Insulin aspart (Fiasp)
Marketed by Novo Nordisk
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2028 · NCT07652528 (registry estimate)
No aligned efficacy figure on record for this race.
insulin glulisine · Apidra
Marketed by Sanofi
NCT00290927 · Phase 3 · completed
The trial randomized 390 participants but was not blinded; the registry describes comparisons with oral diabetes therapy. Its primary efficacy endpoint was change in HbA1c, a surrogate measure, and because no results are posted, it is not possible to determine whether the primary comparison was met.
Reported efficacy
Compare the change in glycemic control (as measured by A1c) from baseline to endpoint of fixed dose bolus regimen vs. variable bolus regimen based on carbohydrate count: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly. (met)
Result source: NCT00135057
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Insulin aspart (Fiasp) | insulin glulisine |
|---|---|---|
| HbA1c, change | 6.6% vs 6.6%vs NovoRapidNCT018191292 other results
| -0.5% vs -0.5%vs Insulin LisproNCT011942582 other results
|
| Body weight, change (kg) | 1.2 vs 1.1vs NovoRapidNCT03268005 | 0.5 vs 0.2vs Insulin Glargine+Metformin+GlimepirideNCT003606981 other result
|
| HbA1c below 7% | —Not reported | 22.4% vs 8.8%vs Insulin Glargine+Metformin+GlimepirideNCT003606981 other result
|
| Fasting plasma glucose, change | 0.6 vs 0.7vs NovoRapidNCT03268005 | —Not posted · NCT00135057 |
| 3-point MACE (% with event) | —Not reported | —Not posted · NCT00135057 |
HbA1c, change
- Insulin aspart (Fiasp)
- 6.6% vs 6.6%vs NovoRapidNCT01819129
2 other results
- -0.1% vs -0.1% NCT03268005
- 6.8% vs 7.7% NCT01850615
- insulin glulisine
- -0.5% vs -0.5%vs Insulin LisproNCT01194258
2 other results
- -2.5% vs -2.1% NCT00384085
- -0.4% vs -0.1% NCT00360698
Body weight, change (kg)
- Insulin aspart (Fiasp)
- 1.2 vs 1.1vs NovoRapidNCT03268005
- insulin glulisine
- 0.5 vs 0.2vs Insulin Glargine+Metformin+GlimepirideNCT00360698
1 other result
- 1.5 vs 1.6 NCT01194258
HbA1c below 7%
- Insulin aspart (Fiasp)
- —Not reported
- insulin glulisine
- 22.4% vs 8.8%vs Insulin Glargine+Metformin+GlimepirideNCT00360698
1 other result
- 51.1% vs 39.5% NCT00384085
Fasting plasma glucose, change
- Insulin aspart (Fiasp)
- 0.6 vs 0.7vs NovoRapidNCT03268005
- insulin glulisine
- —Not posted · NCT00135057
3-point MACE (% with event)
- Insulin aspart (Fiasp)
- —Not reported
- insulin glulisine
- —Not posted · NCT00135057
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Insulin aspart (Fiasp): 4 of 4 rows · insulin glulisine: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Insulin aspart (Fiasp) Rows use multiple source trials | insulin glulisine Rows use multiple source trials |
|---|---|---|
| Dropout rate | 12.8%a NCT01819129 · Phase 3 show 2 more results7.8% NCT01850615 · Phase 3 · combination 2.7% NCT03268005 · Phase 3 · registry result, not featured evidence | 23.5%Lantus/Apidra-1a NCT00384085 · Phase 4 · registry result, not featured evidence · combination show 4 more results20%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination — NCT00360698 · Phase 4 · registry result, not featured evidence · combination —Aspart-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence —Lispro-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 0.3%a NCT01819129 · Phase 3 show 2 more results1.7% NCT01850615 · Phase 3 · combination — NCT03268005 · Phase 3 · registry result, not featured evidence | 2.6%Lantus/Apidra-1a NCT00384085 · Phase 4 · registry result, not featured evidence · combination show 4 more results2.6%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination — NCT00360698 · Phase 4 · registry result, not featured evidence · combination —Aspart-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence —Lispro-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 4.4%a NCT01819129 · Phase 3 show 2 more results5.2% NCT01850615 · Phase 3 · combination 7% NCT03268005 · Phase 3 · registry result, not featured evidence | 11.9%Lantus/Apidra-1a NCT00384085 · Phase 4 · registry result, not featured evidence · combination show 4 more results11.3%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 2% NCT00360698 · Phase 4 · registry result, not featured evidence · combination 6.5%Aspart-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence 0%Lispro-PH20 NCT01194258 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a urinary tract infection 5.9% nasopharyngitis 5% upper respiratory tract infection 4.7% NCT01819129 · Phase 3 show 2 more resultsdiarrhoea 1.7% NCT01850615 · Phase 3 · combination nasopharyngitis 5.9% NCT03268005 · Phase 3 · registry result, not featured evidence | a any infections and infestations 42.3% any musculoskeletal and connective tissue disorders 22.7% any gastrointestinal disorders 16.5% NCT00384085 · Phase 4 · registry result, not featured evidence · combination show 3 more resultsany infections and infestations 34% any musculoskeletal and connective tissue disorders 23.2% any nervous system disorders 20.1% NCT00384085 · Phase 4 · registry result, not featured evidence · combination uterine leiomyoma 6.7% arthralgia 6.5% headache 6.5% NCT01194258 · Phase 2 · registry result, not featured evidence upper respiratory tract infection 11.9% diarrhoea 8.5% nasopharyngitis 5.1% NCT01194258 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Insulin aspart (Fiasp)
show 1 more result
insulin glulisine
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin aspart (Fiasp)'s landscape · insulin glulisine's landscape